{"doi":"10.1016/j.jpi.2025.100528","title":"Quantifying partial pathological response rate in prostate cancer patients who underwent neoadjuvant chemotherapy using a novel morphometric approach","abstract":"Accurate assessment of partial pathological response rate (ppRR) to neoadjuvant chemotherapy (NAT) is critical for assessing the efficacy of therapy and for optimal clinical management. Because of a lack of accurate estimation of baseline cancer burden, assessment of ppRR has never been attempted in prostate histologically. We presented a novel morphometric approach assessing ppRR in patients who underwent NAT and then correlated the ppRR with patients' outcomes. A control cohort consisted of 39 NAT-naïve Caucasian patients who had high-risk PCa (defined as Gleason Grade Group >2) and an adequate biopsy sample (defined as the size of the biopsy PCa area, including PCa epithelium and stroma >2 mm2 ). A study cohort included 26 patients with high-risk PCa (defined as clinical stage T3a or higher, serum PSA >20 ng/mL, or GGG of 4–5, or with oligometastatic disease) who underwent androgen deprivation therapy plus docetaxel. Using the PCa epithelial to stromal ratio (E/S) as a metric, surrogate BCB for the study cohort was predicted from the pre-treatment biopsy samples, and ppRR was calculated. Correlation analysis of patients' ppRR with progression-free survival was performed using ppRR >80% as a cut-off. Nine of the 26 patients from the study cohort experienced a significant response to NAT (ppRR > 80%) using the PCa E/S-based approach, and these patients had significantly better progression-free survival ( p = 0.006). ppRR to NAT can be reliably assessed using PCa E/S as a surrogate metric from biopsy and RP samples, and ppRR can be used to predict patients' outcomes. • Using PCa epithelial to stromal ratio (E/S) as a surrogate metric, baseline cancer burden (BCB) were predicted from the pre-treatment biopsy samples, and partial pathological response rates (ppRR) to neoadjuvant chemotherapy (NAT) were calculated. • Nine of the 26 patients in the test cohort had a significant response to NAT (ppRR >80 %, cut-off) and had significantly better progression-free survival ( p = 0.006). • ppRR to NAT can be reliably measured using PCa E/S and can be used to predict patients' outcomes.","journal":"Journal of Pathology Informatics","year":2025,"id":581015,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9547,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":116971,"name":"Huihua Li","orcid":null,"position":1,"is_corresponding":false},{"id":1492411,"name":"Philipos Tsourkas","orcid":null,"position":2,"is_corresponding":false},{"id":275525,"name":"Sean J. McIlwain","orcid":"0000-0002-3820-8400","position":3,"is_corresponding":false},{"id":298238,"name":"Irene M. Ong","orcid":"0000-0002-9353-6941","position":4,"is_corresponding":false},{"id":316488,"name":"Christos E. Kyriakopoulos","orcid":"0000-0002-6452-7405","position":5,"is_corresponding":false},{"id":1492412,"name":"Brian F. G. Johnson","orcid":null,"position":6,"is_corresponding":false},{"id":458800,"name":"Steve Y. Cho","orcid":"0000-0003-2724-7778","position":7,"is_corresponding":false},{"id":388086,"name":"Shane A. Wells","orcid":"0000-0002-1067-6624","position":8,"is_corresponding":false},{"id":1492413,"name":"Alejandro Roldan Alzate","orcid":null,"position":9,"is_corresponding":false},{"id":329212,"name":"David F. Jarrard","orcid":"0000-0001-8444-7165","position":10,"is_corresponding":false},{"id":715579,"name":"Erika Héninger","orcid":"0000-0003-0166-9972","position":11,"is_corresponding":false},{"id":395994,"name":"Joshua M. Lang","orcid":"0000-0002-0943-8872","position":12,"is_corresponding":false},{"id":445695,"name":"Wei Huang","orcid":"0000-0003-0813-4188","position":0,"is_corresponding":true}],"reference_count":21,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:58:43.046112Z","pmid":"41438589","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}